NCT03338114View on ClinicalTrials.gov

Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2017

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Amyotrophic Lateral SclerosisFasciculation
Interventions
DRUG

FLX-787-ODT (orally disintigrating tablet)

Oral Disintegrating Tablet

Trial Locations (1)

27157

Wake Forest University Health Sciences, Winston-Salem

Sponsors

Lead Sponsor

Flex Pharma, Inc.
All Listed Sponsors
lead

Flex Pharma, Inc.

INDUSTRY